Rottapharm Report issue

Founded: Monza Italy (1994)
Status: Acquired by Meda Pharmaceuticals (2014) → now Mylan (2016)

Organization Overview

First Clinical Trial
2000
NCT00110474
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Rottapharm Biotech | Rottapharm S.L.